The small, 48-subject study – published ... in Boston is running a four-week pilot study comparing Eli Lilly's dual GIP/GLP-1 tirzepatide to placebo in around 20 AUD patients, focusing on ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo ... Novo has struggled to stay competitive with Eli Lilly LLY in developing the next ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Here are the small steps they're taking this year to get there. There is only one GLP-1 pill on the market, and it's not as effective as Ozempic for weight loss.Grace Cary/Getty Images Eli Lilly ...

Eli Lilly (NYSE: LLY) announced its full results and reiterated its earlier 2025 forecast. The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been ...